Preclinical research revealed that targeted monocytes and inflammatory macrophages that specifically express carboxylesterase 1 could achieve therapeutic benefit in IBD38, however, whether they could prevent intestinal fibrosis and CF formation was not reported. The gene discussed is CES1; the disease is cystic fibrosis.